Immutep Limited (FRA:YP1B)

Market Cap	42.08M -78.7%
Revenue (ttm)	12.07M +295.2%
Net Income	-48.02M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0170
Previous Close	0.0165
Day's Range	0.0170 - 0.0170
52-Week Range	0.0060 - 0.2500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 11, 2026

About Immutep

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 31
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: YP1B

Financial Performance

In fiscal year 2026, Immutep's revenue was 19.93 million, an increase of 295.22% compared to the previous year's 5.04 million. Losses were -79.30 million, 29.1% more than in 2025.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 8, 2026

Data Sources Report a data error